blog

Investor interest in AI scribes is expanding — from clinician documentation to patient-side care navigation. Abridge, Suki, Commure, Heidi, and now Kin show different bets on the s...

Plain-English medical summaries are useful. They can also be dangerous if users cannot distinguish between what the doctor said, what the AI inferred, and what the evidence support...

If patients increasingly leave with AI-generated summaries, clinicians need to become more intentional about verbal safety-netting — because the AI will summarise exactly what it h...

The US has consumer health monetisation pathways. The UK has NHS governance and public-sector trust. Patient-facing AI scribes will scale differently in each system.

The strongest use case for patient-facing AI scribes may not be young tech-savvy patients — it may be caregivers managing elderly relatives, complex chronic disease, or post-discha...

Kin and Heidi should not be compared as if they are the same product. One is patient-side visit memory. The other is clinician-side documentation. The distinction matters.

Patient-facing AI summaries are promising — but the harm profile differs from clinician scribes. The risk is a patient acting on an inaccurate summary without any clinical review.

Clinicians will increasingly encounter patients who record consultations using AI apps. The practical question is not whether this can be stopped — but how to communicate safely an...

The most interesting part of Kin may not be the notetaking. It is the GoodRx-like thesis: free patient utility, monetised downstream through referrals, labs, and prescriptions.

Patient-side AI scribes raise different legal and ethical questions from clinician-side ambient scribes. Here is what UK clinicians need to know about patients recording consultati...

The 'AI scribe' label hides three separate markets: clinician documentation, patient memory, and clinical reasoning. Understanding the split helps clinicians and organisations choo...

Kin Health and Aide Mirror are both patient-facing AI scribes — but they emerge from different health-system contexts: US consumer health vs UK NHS-adjacent patient engagement.